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Liver cirrhosis in sub-Saharan Africa: neglected, yet important
Clinical efforts and research on liver diseases have been 
scarce in sub-Saharan Africa. The first Conference on 
Liver Disease in Africa (Nairobi, Sept 13–15, 2018), 
gathering all stakeholders from the continent, is a 
welcome step towards greater attention to the problem, 
and the important issue of liver cirrhosis.
Cirrhosis-related deaths doubled in sub-Saharan 
Africa between 1980 and 2010, and the Central 
African Republic, Gabon, Malawi, Uganda, and Cote 
d’Ivoire were among the highest 10% of countries for 
these deaths in 2010.1 Most cases of cirrhosis were 
attributed to hepatitis B virus (HBV), alcohol misuse, 
and hepatitis C virus (HCV), but around 30% were 
unrelated to these causes.1 The understudied non-
alcoholic fatty liver disease probably has a role in these 
latter cases, considering the increase in obesity in sub-
Saharan Africa, and traditional herbal medicine could 
also contribute, because its use is associated with a 
substantial increase in liver fibrosis.2,3
Treatment of liver cirrhosis is inaccessible in most 
parts of sub-Saharan Africa, given the huge shortage of 
hepatologists and gastroenterologists, interventional 
radiologists, hepatobiliary surgeons, and pathologists. 
Liver transplants are uncommon and done only in South 
Africa, and the costs are prohibitive for the governments 
of almost all sub-Saharan countries.
How should we tackle the high burden of cirrhosis in 
sub-Saharan Africa, where more than 50% of patients 
are admitted to hospital with end-stage disease (due to 
poverty, limited confidence in Western medicine, trust in 
traditional medicine, or distance from suitable hospitals) 
and mortality is high at initial hospitalisation?4
Public awareness and high-level government 
commitment are needed. Preventive measures must 
involve reliable screening of transfused blood for viral 
hepatitis; improved hygiene in health facilities; training 
or retraining of health-care workers on safe injection 
practices; vaccination of relatives, cohabitants, and 
long-term sexual partners of HBV carriers; and health 
promotion and education programmes to reduce 
alcohol consumption, excessive weight, and diabetes. 
Appropriate lifestyle messages should be spread by 
local opinion leaders, through radio programmes and at 
meetings of community and faith-based organisations. 
Nurses in rural and underserved area clinics could also 
play an important role. Diagnostic services must be 
decentralised to the provinces of countries and include 
use of point-of-care rapid diagnostic tests, including 
nucleic acid tests,5 the prices of which will probably 
decrease with extended use.
Earlier diagnosis of liver fibrosis is essential. Transient 
elastography should be made available in referral 
hospitals, and screening campaigns should be organised 
in areas where the prevalence of HBV or HCV infection 
is high.6 Treatment of chronic liver disease must be 
improved and extended. Oral antiviral drugs for hepatitis 
B are easier to administer, and tenofovir and entecavir 
have excellent resistance profiles. However, treatment 
is lifelong and, therefore, costly, so generic formulations 
should be made available at low prices. Mass treatment 
for HBV infection with generic entecavir could be 
achieved at a low cost.7 Although progress has been made 
in lowering the prices and increasing the availability of 
oral, direct-acting antivirals for chronic hepatitis C, much 
remains to be done for the HCV epidemic to be tackled in 
sub-Saharan Africa.8 The availability of affordable point-
of-care diagnostics and oral drugs could also facilitate 
shifting of treatment to the primary care level.
African governments must invest in hepatology 
services. The main referral hospitals in each country 
should have efficient liver units and clinics, possibly 
established with help from private institutions; proper 
equipment and instrument maintenance should be 
ensured. The high fatality rate of complications, such 
as oesophageal variceal bleeding, must be reduced 
by solving problems in resuscitation and blood 
supply, increasing the availability of Sengstaken-
Blakemore tubes, and facilitating referrals and access 
to therapeutic endoscopy.9 Liver biopsy should be done 
more often in referral hospitals, in which well equipped 
pathology departments are essential to improvement 
of diagnostics for autoimmune liver diseases, Wilson’s 
disease, and haemochromatosis, for example. 
Governments should find the resources to guarantee 
free treatment for poor patients. Medical schools in 
sub-Saharan Africa should train more hepatologists 
and gastroenterologists, interventional radiologists, 
hepatobiliary surgeons, and pathologists. Salaries 
should be sufficiently attractive in referral hospitals 
to retain these specialists and not lose them to private 
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hospitals and clinics. When decompensated cirrhosis 
(end-stage liver disease) develops, palliative care services 
are needed, but they are present almost exclusively in 
South Africa and should be made more available.
Prevention, early diagnosis, and treatment of liver 
cirrhosis deserve serious attention from the governments 
of sub-Saharan African countries and civil society, as 
well as by the medical and nursing communities. It is 
a growing issue that must be properly confronted to 
reduce considerable morbidity and mortality.
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